M1 Kliniken AG Stock
M1 Kliniken AG Stock
M1 Kliniken AG dominated the market today, gaining €1.25 (7.940%).
So far the community has only identified positive things for M1 Kliniken AG stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of M1 Kliniken AG in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of M1 Kliniken AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| M1 Kliniken AG | 7.940% | 26.103% | 28.947% | 130.511% | 54.505% | 67.317% | - |
| Vita 34 AG | 8.790% | -4.158% | 7.556% | -32.213% | -7.634% | -70.488% | -66.154% |
| Capital Senior Living Corp. | -1.960% | 2.041% | 14.504% | 354.545% | 246.821% | -21.466% | -44.994% |
| Surgery Partners Inc | 3.510% | 2.609% | -6.349% | -25.786% | -18.056% | -45.116% | 143.953% |
News
EQS-Adhoc: M1 Kliniken AG decides to start share buyback
EQS-Adhoc: M1 Kliniken AG decides to start share buyback
EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2023: M1 continues to grow - sales growth of over 10% to € 316,3 million; EBIT increases by 68% to € 15.7 million
EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2023: M1 continues to grow - sales growth of over 10% to € 316,3 million; EBIT increases by 68% to € 15.7 million
EQS-News: M1 Kliniken AG: Private equity interested in beauty segment, EBITDA of over EUR 27 million expected in 2024
EQS-News: M1 Kliniken AG: Private equity interested in beauty segment, EBITDA of over EUR 27 million expected in 2024